A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: Pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 472-481

  Nakajima, Hidemitsu ^a   Kakui, Nobukazu ^a   Ohkuma, Kunihiro ^a   Ishikawa, Midori ^a   Hasegawa, Toshifumi ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 3,57,8 TETRAHYDROTHIOPYRANO[4,3,D] PYRAMIDINE 4 ONE]; DR 2313; GLUTAMIC ACID; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NORPHENAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL DEATH; CEREBROVASCULAR ACCIDENT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPYRINE; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; BRAIN ISCHEMIA; CELLS, CULTURED; CEREBRAL INFARCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; FREE RADICAL SCAVENGERS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; NEUROPROTECTIVE AGENTS; POLY(ADP-RIBOSE) POLYMERASES; PYRIMIDINONES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 13244267045     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075465     Document Type: Article

References (37)

1. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C, and Endres M (2001) Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med 7:255-260.
2. Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Hoger T, Menissier-de Murcia J, and de Murcia G (1999) PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274:17860-17868.
3. Andersson Y, Bergstrom M, and Langstrom B (1994) Synthesis of 11C-labelled benzamide compounds as potential tracers for poly(ADP-ribose) synthetase. Appl Radiat Isot 45:707-714.
4. Banasik M, Komura H, Shimoyama M, and Ueda K (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569-1575.
5. Callaway JK, Beart PM, and Jarrott B (1998) A reliable procedure for comparison of antioxidants in rat brain homogenates. J Pharmacol Toxicol Methods 39:155-162.
6. Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2-14.
7. Chiarugi A (2002) Poly(ADP-ribose) polymerase: killer or conspirator? The "suicide hypothesis" revisited. Trends Pharmacol Sci 23:122-129.
8. Chiarugi A, Meli E, Calvani M, Picca R, Baronti R, Camaioni E, Costantino G, Marinozzi M, Pellegrini-Giampietro DE, Pellicciari R, et al. (2003) Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp Ther 305:943-949.
9. Costantino G, Macchiarulo A, Camaioni E, and Pellicciari R (2001) Modeling of poly(ADPribose) polymerase (PARP) inhibitors: docking of ligands and quantitative structure-activity relationship analysis. J Med Chem 44:3786-3794.
10. Czapski GA, Cakala M, Kopczuk D, and Strosznajder JB (2004) Effect of poly(ADP-ribose) polymerase inhibitors on oxidative stress evoked hydroxyl radical level and macromolecules oxidation in cell free system of rat brain cortex. Neurosci Lett 356:45-48.
11. D'Amours D, Desnoyers S, D'Silva I, and Poirier GG (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342:249-268.
12. Dawson VL and Dawson TM (1998) Nitric oxide in neurodegeneration. Prog Brain Res 118:215-229.
13. de Murcia G and Menissier de Murcia J (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19:172-176.
14. Eliasson MJ, Sampei K, Mandir AS, Hum PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, et al. (1997) Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3:1089-1095.
15. Endres M, Wang ZQ, Namura S, Waeber C, and Moskowitz MA (1997) Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 17:1143-1151.
16. Ferraris D, Ko Y-S, Pahutski T, Ficco RP, Serdyuk L, Alemu C, Bradford C, Chiou T, Hoover R, Huang S, et al. (2003) Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. II. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J Med Chem 46:3138-3151.
17. Ha HC and Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96:13978-13982.
18. Ishii T, Sunami O, Nakajima H, Nishio H, Takeuchi T, and Hata F (1999) Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. Biochem Pharmacol 58:133-143.
19. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, and Saito KI (1997) Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 281:921-927.
20. Komjati K, Mabley JG, Virag L, Southan GJ, Salzman AL, and Szabo C (2004) Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 13:373-382.
21. Longa EZ, Weinstein PR, Carlson S, and Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91.
22. Markgraf CG, Velayo NL, Johnson MP, McCarty DR, Medhi S, Koehl JR, Chmielewski PA, and Linnik MD (1998) Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 29:152-158.
23. Marsischky GT, Wilson BA, and Collier RJ (1995) Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation: evidence for active site similarities to the ADP-ribosylating toxins. J Biol Chem 270:3247-3254.
24. Moroni F, Meli E, Peruginelli F, Chiarugi A, Cozzi A, Picca R, Romagnoli P, Pellicciari R, and Pellegrini-Giampietro DE (2001) Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 8:921-932.
25. Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, and Dirnagl U (1998) Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 18:196-205.
26. Pieper AA, Blackshaw S, Clements EE, Brat DJ, Krug DK, White AJ, Pinto-Garcia P, Favit A, Conover JR, Snyder SH, et al. (2000) Poly(ADP-ribosyl)ation basally activated by DNA strand breaks reflects glutamate-nitric oxide neurotransmission. Proc Natl Acad Sci USA 97:1845-1850.
27. Pieper AA, Verma A, Zhang J, and Snyder SH (1999) Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20:171-181.
28. Szabo C and Dawson VL (1998) Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287-298.
29. Takahashi K, Greenberg JH, Jackson P, Maclin K, and Zhang J (1997) Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17:1137-1142.
30. Takahashi K, Pieper AA, Croul SE, Zhang J, Snyder SH, and Greenberg JH (1999) Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res 829:46-54.
31. Tanaka M (2002) Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nippon Yakurigaku Zasshi 119:301-308.
32. Tanuma S and Kanai Y (1982) Poly(ADP-ribosyl)ation of chromosomal proteins in the HeLa S3 cell cycle. J Biol Chem 257:6565-6570.
33. Tokime T, Nozaki K, Sugino T, Kikuchi H, Hashimoto N, and Ueda K (1998) Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain. J Cereb Blood Flow Metab 18:991-997.
34. Virag L and Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429.
35. Watanabe T, Yuki S, Egawa M, and Nishi H (1994) Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268:1597-1604.
36. Yu S-W, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, and Dawson VL (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (Wash DC) 297:259-263.
37. Zhang J, Lautar S, Huang S, Ramsey C, Cheung A, and Li JH (2000) GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 278:590-598.